BiotechTube
EnPlusOne Biosciences

EnPlusOne Biosciences

Cambridge, United States· Est.
enplusone.bio
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $12M

Overview

EnPlusOne Biosciences is a private, pre-revenue platform company founded in 2021 and based in Cambridge, Massachusetts. It has developed the ezRNA™ platform, a flexible, enzymatic RNA synthesis technology that operates in water and promises unrestricted scale, access to novel modifications, and efficient production of long RNA sequences. The company is positioned to partner with drug developers to enable advanced RNA therapeutics, addressing a critical bottleneck in the rapidly growing field.

RNA TherapeuticsSynthetic Biology

Technology Platform

ezRNA™: A flexible enzymatic platform for RNA synthesis using a universal enzyme in water. Enables scalable, template-free production of long and modified RNA, including novel nucleobases, sugar modifications, and backbone chemistries.

Funding History

1
Total raised:$12M
Seed$12M

Opportunities

The rapid growth of the RNA therapeutics market is creating a severe manufacturing bottleneck, especially for long, complex, and modified RNAs.
EnPlusOne's enzymatic platform is positioned to capture this demand by offering a scalable, cost-effective, and chemically versatile alternative to traditional synthesis.
Furthermore, enabling access to >200 natural modifications opens a new design space for next-generation drugs.

Risk Factors

The platform must prove it can achieve commercial-scale manufacturing with consistent purity and yield to displace entrenched chemical methods.
As a pre-revenue platform company, success is entirely dependent on convincing risk-averse pharmaceutical partners to adopt a new, unproven technology.
It also faces competition from both established CDMOs and other startups innovating in RNA synthesis.

Competitive Landscape

EnPlusOne competes with established contract development and manufacturing organizations (CDMOs) using traditional phosphoramidite chemistry, as well as other biotech startups developing novel enzymatic or hybrid synthesis methods (e.g., Ansa Biotechnologies). Large mRNA players like Moderna and BioNTech may also develop internal enzymatic capabilities. The key differentiator is claimed access to a broader modification palette and scalable long RNA synthesis.

More companies in RNA Therapeutics (non-mRNA) →More companies in United States →